A proposed ban on direct-to-consumer prescription drug advertising could spell trouble for the industry's biggest ad spender.
When done right, deepwater exploration can create a lot of value, but a big miss can obliterate shareholder value.
Johnson & Johnson's newly approved multiple myeloma drug, Darzalex, is worth keeping an eye on for a number of reasons.
Some risk can still be taken, but safety and preservation of capital should be priorities.
The world's largest retailer's latest strategy is starting to pay off.
Low oil prices might be the theme of today, but the opposite storyline could be just up on the horizon.
IBM's stock price is dwindling, and its valuation is tempting; is Buffet making a trademark contrarian investment in IBM with few investors truly taking notice?
While other investors were selling, Warren Buffett, George Soros, and Carl Icahn were busy buying these stocks last quarter.
Management wanted to put any concerns about BP to bed during its recent conference call, and really went out of its way to make sure investors knew what they had planned for years to come.
The streaming wars just got a lot more interesting with a major victory for Sony's PlayStation Vue. However, don't expect this to upend the cable industry overnight.